(16322749), M. A. Y., (16515247), A. A. H., (16515249), R. M. H., (16515250), A. M. B., (16515253), A. M. A., (9072038), P. C., & (16328993), A. J. N. (2021). Dasatinib versus nilotinib as upfront therapy for treatment naïve chronic myeloid leukemia chronic phase.
Chicago Style (17th ed.) Citation(16322749), Mohamed A. Yassin, Anas A. Hamad (16515247), Radwa M. Hussein (16515249), Ahmed M. Basha (16515250), Ahmad M. Adel (16515253), Prem Chandra (9072038), and Abdulqadir J. Nashwan (16328993). Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase. 2021.
MLA (9th ed.) Citation(16322749), Mohamed A. Yassin, et al. Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase. 2021.